Syndax Pharmaceuticals, Inc. - SNDX
About Gravity Analytica
Recent News
- 12.12.2025 - Revuforj® (revumenib) Named Best New Drug at the Scrip Awards 2025
- 12.08.2025 - Syndax Highlights Leadership in Menin Inhibition at ASH 2025 with Multiple Revuforj® (revumenib) Presentations Spanning the Acute Leukemia Treatment Continuum
- 12.03.2025 - Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
- 11.05.2025 - Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
- 11.03.2025 - Syndax Reports Third Quarter 2025 Financial Results and Provides Business Update
- 11.03.2025 - Syndax Announces Compelling Revuforj® (revumenib) and Niktimvo™ (axatilimab-csfr) Data Accepted for Presentation at ASH 2025
- 11.03.2025 - Syndax to Host ASH Investor Event in Person and via Webcast on December 8, 2025
- 10.30.2025 - Syndax Announces Participation in November Investor Conferences
- 10.27.2025 - Syndax to Announce Third Quarter 2025 Financial Results and Host Conference Call and Webcast on November 3, 2025
- 10.24.2025 - Syndax Announces FDA Approval of Revuforj® (revumenib) in Adult and Pediatric Patients with Relapsed or Refractory NPM1 Mutated Acute Myeloid Leukemia